Today’s deal between Bristol Myers Squibb Company and Orum Therapeutics is by no means the biggest over antibody-drug conjugates to have been signed this year, but is notable for the interesting combination of technologies it employs.
BMS Spends $100m On Orum’s Antibody-Guided Protein Degrader
ORM-6151 combines two hot approaches in cancer R&D, but clinical trials have not yet started.
